Viral infections remain a major cause of morbidity and mortality after pediatric hematopoietic stem cell transplantation. Adoptive transfer of donor-derived virusspecific T cells can reconstitute antiviral immunity in recipients and be effective both in preventing and treating cytomegalovirus, Epstein-Barr virus and adenovirus infection. Current efforts are focused on providing protection toward a broader range of viruses safely, rapidly and effectively.
Introduction
During the period of immune recovery after hematopoietic stem cell transplantation (HSCT) viral infections, which are normally controlled by T cell immunity are an important cause of morbidity and mortality. The degree of risk for infection is dictated by the degree of tissue mismatch between donor and recipient, and the resultant degree of immunosuppression. Reactivations of latent viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex and herpes zoster are common and often cause symptomatic disease. Respiratory viruses such as adenovirus, influenza and respiratory syncytial virus also frequently cause infection. Antiviral pharmacologic agents are effective against only some of these viruses; their use is costly, associated with significant toxicities and the outgrowth of drug-resistant mutants. As the delay in recovery of virus-specific cellular immune response is clearly associated with viral reactivation and disease in these patients, cellular immunotherapy to restore virus-specific immunity is an attractive option. In this review, we focus on how immunotherapy strategies have been applied to target three common viruses CMV, EBV and adenovirus.
Viral infection post-HSCT
Cytomegalovirus Cytomegalovirus (CMV) is a lytic virus that usually causes an asymptomatic infection in immunocompetent individuals. It is latent in approximately 70% of healthy adults and replicates in epithelial cells, fibroblasts and monocytes. Reactivation of CMV in the stem cell recipient can result in significant morbidity and mortality with clinical manifestations including interstitial pneumonitis, gastroenteritis, fever, hepatitis, encephalitis and retinitis.
1 Cell-mediated immunity is considered the most important factor in controlling CMV infection and CMV-specific CD4 þ and CD8 þ lymphocytes play an important role in immune protection after both primary infection and reactivation of latent disease. The most frequently used drugs for prophylactic or pre-emptive therapy are ganciclovir and foscarnet and these drugs have been successful in reducing mortality associated with CMV disease and in preventing early CMV disease in combination with intravenous immunoglobulin. However, both have significant side effects including neutropenia and nephrotoxicity.
Epstein-Barr virus
Epstein-Barr virus (EBV) is a g-herpesvirus that infects more than 95% of the world's population. Primary infection usually produces a mild self-limiting disease, which is followed by latent infection in B cells and productive replication in B cells and mucosal epithelium. There are at least four types of viral latency with type 1 expressing only the virus nuclear antigen 1 (EBNA1), type 2 expressing in addition to EBNA1, the latent membrane proteins and type 3 expressing all the eight latencyassociated proteins including the immunodominant EBNA3 viral antigens. 2 In these types of latency, the viral small RNAs (EBERs) are abundantly expressed as well as transcripts from the BamHI-A region of the viral genome. In the fourth type of latency, found in the majority of circulating B cells of healthy individuals, viral genes cannot be detected at all. In immunocompromised hosts, the outgrowth of B cells expressing type 3 latency, which are highly susceptible to virus-specific T cells, may lead to the development of post transplant lymphoproliferative disease (PTLD). The overall incidence of PTLD after HSCT is less than 1% but the incidence is increased in recipients with an underlying diagnosis of immunodeficiency and for recipients of stem cells from unrelated or human-leukocyteantigen (HLA)-mismatched donors who receive grafts that are selectively depleted of T cells to prevent graft-versushost disease (GVHD). [3] [4] [5] Few small molecule drugs affect B cells that are already transformed by EBV although nucleoside analogs, like ganciclovir, do inhibit its replicative cycle. Chemotherapy is rarely effective and is associated with significant toxicity. One option for prophylaxis and treatment of PTLD after HSCT is rituximab, a monoclonal antibody against the B-cell phenotypic antigen, CD20. Response rates to rituximab between 55 and 100% have been reported in different series. [5] [6] [7] However, not all patients respond and rituximab produces depletion of normal B cells for more than 6 months. This can be problematic in a patient population that is already immunosuppressed.
Adenovirus
Adenovirus is a nonenveloped lytic DNA virus and humans are susceptible to infection with 51 serotypes of adenovirus forming six distinct groups (A-F). Generally mucosal epithelium is infected but the serotypes differ in their tissue specificity and virulence. Although acute infection is rarely fatal in healthy adults; it is a significant cause of morbidity and mortality in immunocompromised individuals with a wide range of clinical syndromes including pneumonia, hemorrhagic cystitis, nephritis, colitis, hepatitis and encephalitis. Adenovirus has a particularly high incidence after pediatric HSCT. 8 Several reports have shown that clearance of adenovirus infection is associated with the detection of adenovirus-specific T cells 9, 10 and the recovery is significantly delayed in recipients of matched, unrelated donor and haploidentical transplant when intensive immunosuppression such as Campath is used. 10 The most frequently used drug for the treatment is Cidofovir but the associated nephrotoxicity is a major concern; prospective, randomized and controlled trials are required to confirm its efficacy.
Adoptive immunotherapy
Since recovery of virus-specific T cells is clearly associated with protection from infection with each of these viruses, 9, 11, 12 adoptive immunotherapy is an attractive alternative approach to reconstitute antiviral immunity. Both unmanipulated T cells and virus-specific T cells generated by repeated stimulation with antigen-presenting cells expressing viral antigens have been evaluated in clinical trials to prevent and treat the viral infections.
Unmanipulated donor lymphocytes
Unmanipulated donor lymphocyte infusions will contain virus-specific T cells with particularly high frequencies for latent viruses such as CMV and EBV. 13, 14 The Sloan Kettering group initially showed that transferring unmanipulated lymphocytes from EBV-seropositive donors can restore the immune response to EBV and eradicate PTLD 15 ; similar observations of clinical activity have been made for other viruses. 16 However, these products will also contain a high frequency of alloreactive cells so that there is a significant risk of GVHD.
17
Donor T cells transduced with suicide genes One of the means for reducing the risk of GVHD is to transduce the donor T cells with a suicide gene that can be activated if the recipient develops GVHD. The most commonly used suicide gene is the herpes simplex virus thymidine kinase (HSV-tk) that renders transduced T cells sensitive to the cytotoxic effects of ganciclovir. HSV-tk transduced T cells have been evaluated in several clinical trials and when given early post transplant can reconstitute virus-specific immunity 18 while allowing control of GVHD by ganciclovir-induced elimination of the transduced T cells in patients who develop GVHD. However, as the viral thymidine kinase suicide gene is a foreign antigen, therefore, subjected to cytotoxic T lymphocyte (CTL)-mediated immune elimination, new non-immunogenic suicide genes based on inducible Fas-and Caspase9-FK binding domain chimeras have been developed. These molecules mediate inducible T-cell apoptosis dependent on a dimerization process that can be activated by a non-toxic chemical inducer of dimerization. 19 Allodepleted T cells An alternative approach to the problem of alloreactivity is to selectively deplete the T-cell product of alloreactive cells that upregulate activation markers in response to alloantigenic stimulation. Several studies have evaluated the strategy of using CD25 immunotoxin to deplete alloreactive T cells ex vivo [20] [21] [22] and small numbers of allodepleted haploidentical donor cells accelerated anti-viral immune recovery in the recipient. 21 Antigen-specific T cells Another approach to avoid alloreactivity is to generate antigen-specific T cell lines by repetitive ex vivo stimulation with viral antigens. There are several considerations in developing protocols for generating virus-specific CTLs ex vivo. The knowledge of immunodominant antigens that induce protective T cells specific for the targeted virus is required and a delivery system to transfer the antigen to effective antigen-presenting cells must be identified. The antigen-presenting cells must be autologous, express MHC antigens presenting relevant virus-derived peptides as well as co-stimulatory molecules sufficient to induce T-cell activation and expansion. These reagents all need to be suitable for GMP manufacturing, which limits the use of some types and sources of antigen. Clinical trials are summarized in Table 1 .
T-cell therapy for CMV
The first study evaluating whether adoptively transferred T cells could reconstitute anti-viral immunity targeted CMV. In this study, CMV-specific T-cell clones were derived from sibling donors after stimulation with autologous fibroblasts pulsed with CMV. 28 There were no adverse effects and CMV-specific immune responses were reconstituted with none of the patients developing CMV disease or late recurrences. Anti-CMV activity did decline, however, in recipients who did not develop CD4 þ CMVspecific T-cell responses, suggesting that CD4 T cells may be necessary for long-term persistence. In another prophylaxis study, Peggs et al.
30 generated CMV-specific CD4 þ and CD8 þ T cells by stimulation of peripheral blood mononuclear cells (PBMC) with dendritic cells pulsed with CMV antigens derived from a CMV-infected human lung fibroblast cell line. Small doses of CTLs were able to reconstitute immunity with considerable in vivo expansion of CMV-specific CTLs. To avoid the use of live CMV, a more recent study used dendritic cells pulsed with the HLA-A2 restricted peptide NLV derived from CMV-pp65 protein to stimulate CTLs. 32 While this approach also appeared effective, a concern is the restricted specificity of the infused CTLs targeting a single epitope may allow variants to escape and limits the study to patients who are HLA A2-positive.
CMV-specific CTLs have also been used therapeutically in patients with persisting or recurring CMV infection despite prolonged use of anti-viral medication. 29 The results were encouraging with suppression of viral reactivation in 6 of 7 patients. In this study, the source of antigen was a CMV lysate, which has the advantage of producing a broad immune response but which is not suitable for phase III studies because of the risk of infection.
The CTL therapies so far described employed methods of T-cell production that required prolonged periods of activation and expansion and also required specialized GMP facilities and significant regulatory support. This reduces the practicality of adoptive immunotherapy since CTL lines must be made long in advance of the disease and few centers have the facilities or infrastructure required for this type of cell processing. A recently reported clinical trial using tetrameric selection of CMV peptidespecific T cells directly from peripheral blood avoided both Immunotherapy for viral diseases Y Fujita et al ex vivo expansion and live viral antigens. Although exclusively CD8 þ T cells were infused, they expanded by several logs after infusion and in a treatment study, they induced clearance of infection in 8/9 cases. 31 
T-cell therapy for EBV
The outgrowing EBV-infected B cells of PTLD have the same phenotype and viral antigen expression as the EBVtransformed lymphoblastoid cell lines generated by infecting B cells in peripheral blood with a laboratory strain of EBV. As lymphoblastoid cell lines can be readily prepared from any donor, they have been used as antigen-presenting cells in clinical studies evaluating EBV-specific CTLs. 7, 23, 24, 35, 36 EBV-specific CTLs generated using this methodology are polyclonal and contain both CD4-and CD8-positive EBV-specific T cells and recognize multiple latent and lytic viral antigens. We have shown that when used as prophylaxis or therapy, adoptively transferred EBV-specific CTLs can survive for up to 8 years after infusion, could expand up to 2-4 logs after infusion and reduce the high virus load that is observed in about 20% of patients. 35, 36 In a study targeting a high-risk patient population receiving T-cell-depleted marrow, none of the 58 patients who received EBV-CTLs as prophylaxis developed PTLD. 12 Of six patients with active PTLD at the time of infusion, donor-derived EBV-specific CTL lines induced remission in five, while the sixth one in whom the tumor virus sustained had a deletion that removed immunodominant epitopes in EBNA3 that were the main targets for the infused effector T cells. 37 Other studies have confirmed the activity of EBV-specific CTLs post transplant. 7, 24 T-cell therapy for adenovirus Feuchtinger et al. 33 undertook a study in which patients with adenovirus infection were treated with CD4 þ and CD8 þ adenovirus-specific T cells isolated from the donor after a short in vitro stimulation with adenovirus viral antigen followed by the selection of g-interferon-secreting cells. Small numbers of adenovirus-specific donor T cells were infused into nine children with systemic adenovirus infection after HSCT. Adenovirus-specific immune responses were detected in five of six evaluable patients associated with a sustained decrease in viral load and clearance of infection. 33 Multivirus-specific T cells The strategies described above each target one virus. To broaden the specificity of single CTL lines to include the three most common viral pathogens of stem cell recipients, we reactivated CMV and adenovirus-specific T cells by using mononuclear cells transduced with a recombinant adenoviral vector encoding the CMV antigen pp65 (Figure 1 ). Subsequent stimulations with EBVlymphoblastoid cell lines transduced with the same vector then both reactivated EBV-specific T cells and maintained the expansion of the activated adenovirus and CMVspecific T cells. 34 This method reliably produced CTLs with cytotoxic function specific for all the three viruses that were infused into 14 stem cell recipients in a phase I prophylaxis study. We observed recovery of immunity to CMV and EBV in all patients but an increase in adenovirus-specific T cells was seen only in the patients who had evidence of adenovirus infection pre-infusion. 34 All the patients with pre-infusion CMV, adenovirus or EBV infection or reactivation were able to clear the infection including the patient with adenoviral pneumonia. 34 CTLs recognizing multiple antigens can therefore produce clinically relevant effects against all the three viruses.
Future directions
Rapid generation techniques and selection Peptide-HLA tetramers and cytokine-secretion capture columns allow rapid isolation of antigen-specific T cells for adoptive transfer. With tetramer selection, T cells that bind a particular peptide can be isolated magnetically for direct transfer to patients without the need for a prolonged in vitro culture. This approach requires the knowledge of immunodominant epitopes and is restricted by HLA type. While it was successful for selecting the CMV-specific cells that are abundant in peripheral blood, it may have limitations when trying to isolate T cells with lower frequencies. 31 In addition, production of clinical-grade tetramers for use under GMP may limit wider application of this strategy. The capture of T cells that secrete cytokines in response to stimulation with viral antigens also allows rapid T-cell selection as demonstrated for adenovirusspecific T cells. 33 This strategy has the advantage that knowledge of epitopes is not required and there is no HLA restriction, however, it produces small numbers of selected cells from some donors that will be challenging to characterize for phase III studies.
Closely matched allogeneic lines
An alternative approach to bypass the need to grow CTLs for individual patients is to use closely matched banked allogeneic lines that could be available as an 'off the shelf' product. A concern with this approach is that persistence of a mismatched product may be suboptimal as the recipient may generate an immune response to the non-shared HLA antigens. However, a recent Phase II study using EBVspecific CTLs to treat PTLD after solid organ transplant or SCT has shown an encouraging response rate of 64 and 52% at 5 weeks and 6 months respectively with better responses at 6 months achieved in patients who received the most closely HLA-matched CTL lines. 27 In a second report, two solid organ recipients with central nervous system(CNS) lymphoma received closely matched EBVspecific T cells resulting in complete resolution of their brain lesions. 38 This approach therefore warrants further evaluation.
Broadening specificity
As discussed above, it is possible to generate multispecific CTLs with clinical activity against EBV, adenovirus and CMV. However, there are several other community viruses such as HHV6, BK and respiratory viruses, such as respiratory syncytial virus, influenza and parainfluenza that cause significant morbidity and mortality after HSCT and whose control is suboptimal with currently available drugs. Current challenges are to define the protective immune response toward these viruses and to determine if these antigens could be incorporated into current methodologies.
